LGX818, MEK162 and LGX818 vs vemurafenib in melanoma patients.

• Research type

  Research Study

• Full title

  A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanoma.

• IRAS ID

  136687

• Contact name

  Mark Middleton

• Contact email

  mark.middleton@oncology.ox.ac.uk

• Sponsor organisation

  Array BioPharma Inc.

• Eudract number

  2013-001176-38

• ISRCTN Number

  n/a

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  13/SC/0478

• Date of REC Opinion

  21 Oct 2013

• REC opinion

  Further Information Favourable Opinion